TITLE

Treatment pathways, resource use and costs in the management of small cell lung cancer

AUTHOR(S)
Oliver, E.; Killen, J.; Kiebert, G.; Hutton, J.; Hall, R.; Higgins, B.; Bourke, S.; Paschen, B.
PUB. DATE
October 2001
SOURCE
Thorax;Oct2001, Vol. 56 Issue 10, p785
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background-Small cell lung cancer (SCLC) represents about 20% of primary lung tumours and the costs associated with the management of SCLC can be significant. The main objective of this study was to obtain information on current patterns of care and associated resource use and costs for patients with SCLC from initial diagnosis and treatment phase, throughout disease progression and terminal care. Methods-A 4 year retrospective patient chart analysis (1994-7) was conducted on a consecutive series of 109 patients diagnosed with SCLC in two Newcastle hospitals. For this consecutive series of patients all details about care received including tests and procedures, treatment, and medication from diagnosis till death were recorded. Pathways of care and forms were designed to enable resource use to be captured for different disease phases. Unit costs were determined from a variety of sources including the Newcastle Hospitals NHS Trust Finance Department and the British National Formulary. Results-The average total cost per patient calculated for the full cohort of 109 patients was £11556. Initial treatment was the most resource use intensive constituting 48.2% of the total cost. The major cost element throughout all disease phases was hospitalisation. Twenty eight percent of the total costs of care occur after recurrence of the disease until death, of which 73% are generated by terminal care. Conclusion-The results of this retrospective medical chart analysis show that the costs of care of SCLC are considerable, although the variability between patients in terms of the type and quantity of resource use is very high. Analyses such as this provide a useful insight into resources used in actual clinical practice.
ACCESSION #
12991414

 

Related Articles

  • CT screening for lung cancer - cost effectiveness debated.  // PharmacoEconomics & Outcomes News;11/14/2009, Issue 591, p11 

    The article discusses research on the cost effectiveness of computed tomography (CT) screening for non-small cell lung cancer versus symptomatic tumour identification in a U.S. setting. It references a study by A. W. Castleberry et al, published in the September 15, 2009 issue of the "British...

  • Amrubicin.  // Reactions Weekly;10/23/2010, Issue 1324, p11 

    The article describes the cases of seven men with small cell lung cancer who suffered from interstitial lung disease while taking amrubicin.

  • Sarcomatoid Carcinoma of the Lung. Franks, Teri J.; Galvin, Jeffrey R. // Archives of Pathology & Laboratory Medicine;Jan2010, Vol. 134 Issue 1, p49 

    Context.-Sarcomatoid carcinoma of the lung is a subset of poorly differentiated non-small cell lung cancers that are diagnostically challenging because they are uncommon, may reveal little of their parent cell of origin, and overlap morphologically with other anaplastic epithelioid and spindle...

  • Anemia and Limited-stage Small Cell Lung Cancer. Ershler, William B. // Clinical Oncology Alert;Sep2007, Vol. 23 Issue 9, p65 

    There has been much written about the importance and management of anemia in cancer patients this past year. For certain tumors, it is clear that the appearance of anemia prior to therapy confers adverse prognostic implications.1-3 One aspect of the controversy surrounding anemia is whether...

  • FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. Martin H. Cohen // Oncologist;Aug2005, Vol. 10 Issue 7, p461 

    On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY, http://www.osip.com, and Genentech, Inc., South San Francisco, CA, http://www.gene.com) received regular approval as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell...

  • INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.  // BMC Cancer;2011, Vol. 11 Issue 1, p430 

    The article presents a phase III study of the BLP25 liposome vaccine (L-BLP25) in unresectable stage III non-small cell lung cancer (NSCLC) patients in Asia. As stated, the study is the first large study of a therapeutic cancer vaccine for East-Asian population. It evaluates the potential of...

  • The Changing Pattern of Non-Small Cell Lung Cancer Between the 90th and 2000th Decades§. Montesinos, Jesus; Bare, Marisa; Dalmau, Elsa; Saigi, Eugeni; Villace, Pablo; Nogue, Miquel; Segui, Miquel Angel; Arnau, Anna; Bonfill, Xavier // Open Respiratory Medicine Journal;2011, Vol. 5, p24 

    Background: In Europe, approximately 381,500 patients are diagnosed with non-small cell lung cancer (NSCLC) every year. The aim of this study is to analyse the changes in diagnosis, treatment and evolution during the last two decades, using data from a hospital registry. Material and Methods:...

  • Increased CD14HLA-DR myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Huang, Ang; Zhang, Bo; Wang, Bo; Zhang, Fan; Fan, Ke-Xing; Guo, Ya-Jun // Cancer Immunology, Immunotherapy;Sep2013, Vol. 62 Issue 9, p1439 

    Accumulating evidence has demonstrated that myeloid-derived suppressor cells (MDSCs), a heterogeneous population of cells, play an important role in the subversion, inhibition, and downregulation of the immune response to cancer. However, the characteristics of these cells, particularly clinical...

  • MicroRNA-498 is downregulated in non-small cell lung cancer and correlates with tumor progression. Mingxi Wang; Qiang Zhang; Junbin Wang; Yunzhi Zhai // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC107 

    Objective: Non-small cell lung cancer (NSCLC) is the most common type of human lung cancer, with highly aggressive, lethal malignancy and microRNAs have already been proven to be associated with NSCLC tumorigenesis. In this study, we sought to determine the expression, the clinical value and its...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics